Healthcare / Medical Instruments & Supplies

DENTSPLY SIRONA Inc. (XRAY)

$9.83
-1.90%
$2.1B
Market Cap
P/E Ratio
0.94
Beta
5.04%
Dividend Yield
Piotroski 6/9Altman Z 0.5 DistressBeneish M -3.07 CleanROIC−WACC -15.4%

Quantitative Summary

Deterministic

Financial health is average: Piotroski 6/9, Altman Z 0.5.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of DENTSPLY SIRONA Inc. present a severe capital efficiency challenge, characterized by an ROIC-WACC spread of -15.4% and a negative ROE of -44.6%. This poor return on equity is driven primarily by a net margin contraction to -16.2%, which overwhelms the asset turnover rate of 0.68x and moderate leverage of 4.05x, indicating that profitability issues are the dominant drag rather than operational inefficiency or excessive debt. While the Piotroski F-Score of 6/9 suggests some underlying financial stability relative to peers, this is starkly contradicted by an Altman Z-Score of 0.5, signaling a high probability of bankruptcy distress. The divergence between these scores and the persistent negative operating margins highlights significant earnings quality concerns that currently overshadow any potential value signals from management activity.

Valuation metrics reflect substantial downside risk relative to historical norms and sector benchmarks, with current multiples trading at a discount given the company's inability to generate positive free cash flow growth consistent with its implied 10-year trajectory of 12.6%. The market appears pricing in significant structural deterioration rather than recovery, as evidenced by the negative Fama-French alpha of -13.37% annually and a value factor tilt that penalizes the stock's current profile despite robust profitability signals from the RMW factor. Although insider flow shows $1,023,799 net buying over 90 days, this activity occurs within an environment where the Altman Z-Score suggests heightened solvency risks, creating a complex picture where private capital accumulation does not necessarily align with public safety margins or fundamental value creation.

The risk/reward profile is heavily skewed by extreme volatility factors; while the Beneish M-Score of -3.07 offers some reassurance regarding earnings manipulation, it coexists with a negative profitability factor delta that undermines long-term compounding potential. Investors must weigh whether current insider accumulation represents a contrarian bet on eventual margin stabilization or an attempt to mitigate personal exposure during a period where the cost of capital significantly exceeds returns generated by assets. The data suggests a high-risk environment where traditional valuation models may be distorted by distress premiums, requiring careful scrutiny of how quickly operating leverage can reverse before equity value faces further erosion from debt servicing obligations inherent in the negative ROIC spread.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Technical Setup

AI Generated

The current price of XRAY is below both its 50-day and 200-day moving averages, indicating a short-term downtrend relative to recent prices but still within the longer-term range, suggesting potential near-term weakness. With an RSI of 44.1, the security appears to be in a neutral-to-weak position, leaning towards being oversold if it continues to decline further below its current levels.

RSI (14)
SMA 50
SMA 200

Quant Health Deep Dive

6/9
Piotroski F-Score
Average — mixed operational signals
0.5
Altman Z-Score
Distress Zone — below 1.8 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-3.07
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

50.0%
Gross Margin
-16.3%
Net Margin
-7.7%
ROIC
7.7%
WACC
ROIC − WACC Spread: -15.4%— Negative spread.
-3.0%
Revenue Growth (YoY)
+34.3%
Earnings Growth (YoY)
104.0M
Free Cash Flow
123%
FCF Payout Ratio

⚠️ Dividend consumes >80% of FCF — sustainability risk.

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

-16.3%
Net Profit Margin
NI ÷ Revenue
×
0.68x
Asset Turnover
Revenue ÷ Assets
×
4.05x
Equity Multiplier
Assets ÷ Equity
=
-44.6%
Return on Equity
⚠️ High equity multiplier — ROE is being amplified by leverage, not operational excellence.

Balance Sheet Health

3.05x
Debt / Equity
1.51x
Current Ratio
-4.5x
Interest Coverage
2.58%
FCF Yield
-46.0M
EBITDA

Insider Activity (Last 90 Days)

Net Insider Flow
+$1M
Net Buying
4
Buy Transactions
0
Sale Transactions
2026-03-09LUCIER GREGORY TSold 1/8 qtrsBuy$186,675
2026-03-09FORBES JAMES DBuy$62,400
2026-03-04JOHNSON ROBERT ANTHONYGrant44,643 shares
2026-03-04CZERNEY KEVIN J.Grant13,690 shares
2026-03-04DENTI ALDO MARIANO ROBERTOGrant59,524 shares

Open-market buys vs sells by company insiders. Source: yfinance.

Earnings Surprise History

Q4
✓ Beat
Est: $0.30
Act: $0.43
+43.3%
Q3
✓ Beat
Est: $0.50
Act: $0.52
+3.2%
Q2
✗ Miss
Est: $0.45
Act: $0.37
-17.7%
Q1
✗ Miss
Est: $0.29
Act: $0.27
-6.0%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Dividend History

$0.1600
Latest Dividend
$0.64
2025 Total
0.0%
YoY Growth
Annual Dividends per Share
$0.31
2016
$0.35
2017
$0.35
2018
$0.38
2019
$0.40
2020
$0.43
2021
$0.50
2022
$0.56
2023
$0.64
2024
$0.64
2025
DateAmountChange
2025-12-26$0.16000.0%
2025-09-26$0.16000.0%
2025-06-27$0.16000.0%
2025-03-28$0.16000.0%
2024-12-27$0.16000.0%
2024-09-27$0.16000.0%
2024-06-28$0.16000.0%
2024-03-27$0.1600+14.3%
2023-12-28$0.14000.0%
2023-09-28$0.14000.0%
2023-06-29$0.14000.0%
2023-03-30$0.1400+12.0%
Stock Splits
2006-07-18: 2:12002-02-01: 1.5:11997-10-30: 2:11992-08-24: 2:1

Dividend and split data from SEC filings and market data. Amounts are per share, not adjusted for splits. Source: yfinance.

Risk Profile

47.5%
Annual Volatility
-0.06
Sharpe (1Y)
-40.5%
Max Drawdown (5Y)

Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fama-French 5-Factor Exposure

Academic factor model decomposition — what's really driving this stock's returns.

0.92
Market β
Mkt-RF
+1.907
Size (SMB)
Small-cap tilt
-0.780
Value (HML)
Growth tilt
+0.317
Profit (RMW)
Robust
+1.583
Invest (CMA)
Conservative
Alpha (annual): -13.37%
R²: 44.1%of variance explained by 5 factors

Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.

Fundamentals

6.8
Forward P/E
0.71
PEG Ratio
1.56
Price/Book
5M
Avg Volume
$17.09
52W High
$9.41
52W Low
5%
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$37M
Tracked Passive Exposure
8
ETFs Holding XRAY
0.05%
Avg Weight in ETFs
$76B
Total ETF AUM

When investors buy or sell ETFs like XHE or MDYV, the fund manager is mechanically forced to buy or sell XRAY shares regardless of DENTSPLY SIRONA Inc.'s individual fundamentals. We estimate $37M of passive capital is structurally linked to XRAY through 8 tracked ETFs. Passive flows have a limited but growing influence on XRAY's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in DENTSPLY SIRONA Inc. to visualize passive redemption contagion across ETFs and collateral stocks.

XRAY Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
XRAYEpicenterMDYETFVHTETFSPMDETFSTAAUnknownNVCRUnknownGKOSUnknownADBELow RiskAXGNUnknown
XRAY Price Drop (%)0

If DENTSPLY SIRONA Inc. (XRAY) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies STAAR SURGICAL CO (STAA) as the most exposed collateral stock, sharing 1 ETFs with XRAY. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 11 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

XRAY Ownership Dynamics

Passive funds hold 1 in every 27 XRAY shares, reducing daily market volatility.

Ticker
XRAY
Total Shares
200M
ETF Lock-Up
3.7%
Display Mode
Total Float Impact
3.7%Locked Float

DENTSPLY SIRONA Inc. (XRAY) exerts measurable gravity on the passive index market, currently representing 1.3% of the XHE (XHE) and 0.1% of the MDYV (MDYV). Across 13 tracked ETFs, approximately 7M shares (3.7% of float) are held by passive funds and rarely trade on the open market. As passive ownership grows, index inclusion changes may increasingly drive price discovery.

Float lock-up computed from 13 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

XRAY Institutional Volume Profile

252-day volume distribution by price level. The Point of Control (POC) marks the price where the most institutional volume transacted — an implicit support/resistance floor.

TICKER
XRAY
PRICE
$9.83
FLOOR (POC)
$12.48
STRENGTH
High
$10$10$9.83$10$11$1110%$119%$126%$128%$12POC 13%$1310%$13$14$14$14$15$15$15$16$16$16
Focus Zone
Point of Control (POC) Support (below price) Resistance (above price) Current Price

The highest-volume price zone for DENTSPLY SIRONA Inc. over the past year sits near $12.48 (13% of 252-day volume). The current price of $9.83 sits 21.2% below the POC — suggesting potential mean-reversion upside if institutional demand reasserts at this level. The highly concentrated volume profile (13% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.

Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-1351,820$11.00$570,020
2026-04-2483$11.90$987.7
2026-04-2015$12.51$187.65
2026-04-157,673$12.22$93,764.06
2026-04-02283$11.66$3,299.78
2026-03-2577,211$11.47$885,610.17
2026-03-23120$10.95$1,314
2026-03-16258,219$11.54$3.0M
2026-03-039,032$14.31$129,247.92
2026-03-02142,502$14.68$2.1M
2026-02-193,005$12.49$37,532.45
2026-02-1339,897$12.81$511,080.57
2026-02-098,985$13.76$123,633.6
2026-01-284,330$12.77$55,294.1
2026-01-2735,235$12.72$448,189.2
2026-01-0853$12.37$655.61
2026-01-0753$12.37$655.61
2025-12-228,853$11.21$99,242.13
2025-12-164$11.40$45.6
2025-12-0968$11.10$754.8
2025-12-08489$11.25$5,501.25
2025-12-0568$11.27$766.36
2025-11-2611,566$11.09$128,266.94
2025-11-125,579$10.98$61,257.42
2025-10-21518$12.93$6,697.74
2025-10-1442,787$12.21$522,429.27
2025-10-086$12.33$73.98

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Price Correlations

Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.

Peer252-Day (1Y)126-Day (6M)Direction
WTGXXNaNNaN
SWK0.5890.537Moderate
PCAR0.5480.509Moderate
HSIC0.5470.479Moderate
NDSN0.5450.558Moderate
ALGN0.5420.560Moderate
RXO0.5250.469Moderate
DD0.5220.446Moderate
CSL0.5200.485Moderate
BLDR0.5170.482Moderate

Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.

Compare XRAY to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.